BioNexus Gene Lab Corp. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
BioNexus Gene Lab Corp. (BGLC) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -4.73% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-08-14
- BioNexus Gene Lab Corp. effective income tax rate reconciliation, nondeductible expense, percent for the quarter ending 2026-03-31 was -8.83%.
- BioNexus Gene Lab Corp. effective income tax rate reconciliation, nondeductible expense, percent for the quarter ending 2025-03-31 was -1.47%.
- BioNexus Gene Lab Corp. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -6.24%, a 166.45% decline from fiscal 2024.
- BioNexus Gene Lab Corp. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was 9.39%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|---|---|
| 2026-06-30 | -4.73% 10-Q · filed 2026-08-14 | ||
| 2026-03-31 | -8.83% 10-Q · filed 2026-05-15 | ||
| 2025-12-31 | -6.24% 10-K · filed 2026-04-14 | ||
| 2025-06-30 | -0.99% 10-Q · filed 2026-08-14 | ||
| 2025-03-31 | -1.47% 10-Q · filed 2026-05-15 | ||
| 2024-12-31 | 9.39% 10-K · filed 2026-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |